DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

AKI India Share Price: Is It a Good Buy After Q1 FY27 Results?

Univest 1d ago·7 Sept 2026, 6:41 am

AKI India has reported its financial results for the first quarter of fiscal year 2027. The company's performance in this period is being closely watched by the market to gauge its operational health and growth trajectory.

For investors, these results are critical as they provide a snapshot of the company's current momentum. Positive figures could signal strong demand for its products, while any weakness might raise concerns about its competitive position in the industry.

Moving forward, investors should focus on the company's guidance for the upcoming quarters. Monitoring key metrics like sales growth and profit margins will be essential to determine if the stock is a suitable addition to a long-term portfolio.